Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 7,881 matching trials from the live ClinicalTrials.gov search.
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Optimization of Adaptive Rowing Seating

NCT07099625
Conditions
Spinal Cord Diseases, Spinal Cord Injuries, Neurodegenerative Disorders, Cerebrovascular Accident With Associated Sequelae
Interventions
Adaptive Indoor Rowing Seat, Paddle Sport adaptive seating system
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cleveland, Ohio
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Conditions
Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
143
States / cities
Fort Lauderdale, Florida • Savannah, Georgia • Honolulu, Hawaii + 89 more
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Completed No phase listed Observational Accepts healthy volunteers

DPBRN Persistent Pain and Root Canal Therapy

NCT01201668
Conditions
Root Canal Therapy, Persistent Tooth Pain
Interventions
Not listed
Lead sponsor
Dental Practice-Based Research Network
Network
Eligibility
19 Years to 70 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more
Conditions
Cataract
Interventions
C-KAD Ophthalmic Solution, Placebo
Drug
Lead sponsor
Chakshu Research, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • Overland Park, Kansas • Minneapolis, Minnesota + 1 more
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Conditions
Malignant Solid Tumor
Interventions
NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2, NKTR-102 50 mg/m2
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 2 more
Conditions
Ischemic Stroke, MCA Infarction
Interventions
No intervention is planned, this will be a purely retrospective trial.
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Intermittent Claudication, Peripheral Vascular Diseases
Interventions
Treadmill Exercise Training, Arm Ergometry Exercise Training, Usual Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Results available

INtervention Study In overweiGHT Patients With COPD

NCT02634268
Conditions
Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style, Overweight
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
40 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Conditions
Aortic Stenosis
Interventions
SAVR, SAPIEN 3 THV
Procedure · Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 59 more
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • St. Petersburg, Florida • Detroit, Michigan + 3 more
Conditions
Ovarian Carcinoma
Interventions
NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2, NanoPac® 400 mg/m2, Standard of Care Intravenous Chemotherapy
Drug
Lead sponsor
NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 4 more
Conditions
Prostate Cancer
Interventions
Follow-up
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
55 Years to 120 Years · Male only
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
52
States / cities
Fort Lauderdale, Florida • Jupiter, Florida • Miami Beach, Florida + 39 more
Conditions
Myelodysplastic Syndromes
Interventions
Pracinostat, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Duarte, California • San Diego, California • Augusta, Georgia + 21 more
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Support for Alzheimer's Disease Caregivers

NCT00362284
Conditions
Caregivers, Stress, Depression
Interventions
NYUCI-AC
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
laparoscopic surgery
Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Conditions
Childhood Medulloblastoma
Interventions
Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine
Procedure · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
106
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more